SHAREHOLDER ALERT: VRAY MYGN RUHN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / October 18, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Viewray, Inc. (VRAY)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/viewray-inc-loss-submission-form?prid=3979&wire=1
Lead Plaintiff Deadline: November 12, 2019
Class Period: March 15, 2019 to August 8, 2019

Allegations against VRAY include that: (a) demand for ViewRay systems had declined due in part to changes being made to Medicare reimbursement approaches first announced in November 2019 that could make purchases of new ViewRay systems less profitable for customers; (b) the Company's reported backlog was overstated due to the inclusion of orders with insufficient surety as to permit for their inclusion in reported backlog; and (c) as a result of the foregoing, defendants' positive statements about ViewRay's business metrics and financial prospects during the Class Period were materially false and misleading and/or lacked a reasonable basis.

Myriad Genetics, Inc. (MYGN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/myriad-genetics-inc-loss-submission-form?prid=3979&wire=1
Lead Plaintiff Deadline: November 26, 2019
Class Period: September 2, 2016 to August 13, 2019

Allegations against MYGN include that: (i) Myriad's product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration ("FDA") had requested changes to GeneSight and questioned the validity of the test's purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA's requested changes to GeneSight; (iv) Myriad's acquisition of Counsyl-and thereby, Foresight-caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company's revenue; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Ruhnn Holding Limited (RUHN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/ruhnn-holding-limited-loss-submission-form?prid=3979&wire=1
Lead Plaintiff Deadline: December 6, 2019
Class Period: all persons or entities who purchased Ruhnn American Depositary Shares pursuant and/or traceable to the Company's April 3, 2019 initial public offering.

Allegations against RUHN include that: (1) at the time of the initial public offering ("IPO"), the number of Ruhnn's online stores had declined by nearly 40%; (2) at the time of the IPO, the number of Ruhnn's full-service Key Opinion Leaders had declined by nearly 44%; (3) as a result, the Company's net revenues derived from its full-service segment had declined by 46% on a sequential basis; and (3) as a result, defendants' statements about Ruhnn's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

View source version on accesswire.com:
https://www.accesswire.com/563480/SHAREHOLDER-ALERT-VRAY-MYGN-RUHN-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines